New Delhi: The best Indian drug regulator evaluates the Braill Plan labeling on the package of medicine to improve availability for the Indian 4.95 million blind and 70 million visually impaired citizens trying to identify fundamental drug details, the official consciousness of matters and documents reviewed by coin.
The Indian Drug CEO (DCGI) is considering these changes based on a subcommittee report that has recommended to introduce Braill’s signs for drugs wrapped in mono cardboard and for those that often use visually impaired such eye drops.
“There is currently no provision on the labeling in the Act on Drugs and Cosmetics and the rules that consider the needs of blind or visually impaired people,” the panel recommended. “As a result, this special category of people is difficult to know the name and date of the expiration of medicinal products. Therefore, the provisions on the designation of drugs with Braille should be made.”
Recommendations are based on the 2020 representation, which emphasizes the difficulties of visually affected individuals, who are facing reading medical strips. The subcommittee was first created in 2020 and then reconstructed in October 2024 under the KR Chawal, a drug controller and a license body in Delhi, along with three other members.
Also read: Which private hospital is best for you? The new classification system will help patients decide on treatment options
Another advantage
The Committee report also stated that Braille would help fight counterfeit drugs. “According to documents 66. Consultation Meeting with Drugs (DCC) Reviewed Mind could significantly reduce the incidence of duplication of drugs and false products on the market,” according to documents 66. Consulting drug meetings (DCC), which could significantly reduce the incidence of duplication of drugs and false products on the market could significantly reduce drug duplication and false products “. Consultation Meeting with Drugs (DCC).
Indian disturbing or counterfeit drug sales for drugs is awarded at $ 3 billion. The total medicine market in the country is currently awarded at $ 50 billion, according to the Ministry of Pharmaceutical Companies at $ 23.5 billion.
Questions by the spokesperson of the Ministry of Health and Family and DCGI remained unanswered until the press.
First voluntary introduction
Recommendations submitted by the Consulting Committee for Drugs (DCC) On June 17, it is currently being considered to be voluntary or compulsory to start through legislative changes in drug rules of 1945, ”said official conscious affairs and demanded anonymity.
“Initially, it was designed on a voluntary basis, because people (drug manufacturers) would switch to Braille. We also have to see how the Indian industry will adapt to changes. Therefore, it is designed for further designation in Braill’s language to be implemented” on the voluntary basis’ for drugs supplied in the mono -carton package. “
In order to ensure the accuracy of Braille, the subcommittee report recommended that drug manufacturers have their Brailla’s work of art, such as the National Institute for strengthening people with intellectual disabilities (Niepid) through Brailla’s Council of India (BCI) (BCI) or other Niepid points.
Also read: Central movements to improve the services of organ transplants in GOVT hospitals after review shows limiting capacity
The report excluded Braill’s designation for medicines and other pharmaceutical items issued under direct medical supervision, including injection and vaccines. The report also recommends that the competent authority to give advice to retailers and order them to verbally lead visually impaired customers about the names of medicine, dosing, indications, use and expiration date. This instructions would be commonly monitored by officials.
“The introduction of Braill’s labeling for drug production is a good idea. Although 1% of the population gains benefits, it is worth doing, especially for drugs rescue life that are significantly used, and not only restrict it to certain eye drops,” JS TITIYAL, Head of the Eye Institute Dr. Aggarwal in New Delhi and former Chief of RP Eye Center at the All India Institute of Medical Sciences. He said that visually impaired individuals may have other health complications over eye problems.
Dr. S. SACHDEV, Chairman and CEO of Centre for Sight, said Braille’s labeling should be on all kinds of important drugs to rescue life, not just eye drops. However, he expressed reservations about becoming a voluntary requirement.
“We do not know how the manufacturers will be picked up by voluntary initiatives, because it will increase their expenses and logistics problems.”
Also Read: Center Orders Thorough Security Review of Nimesulide Pain for Adults
(Tagstotranslate) braillo
